20/20 Biolabs vs Insight Molecular Diagnostics
AIDX and IMDX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIDX and IMDX compare
Insight Molecular Diagnostics is the larger company, worth 27 times as much as 20/20 Biolabs ($78.2M against $2.9M).
20/20 Biolabs grew revenue faster over the last twelve months (16.7% versus −60.8% for Insight Molecular Diagnostics).
20/20 Biolabs keeps more of each dollar of sales as profit, with a net margin of −183% compared with −2956% at Insight Molecular Diagnostics.
Insight Molecular Diagnostics scores higher on the StockData Score (7 against 6 for 20/20 Biolabs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIDX | IMDX |
|---|---|---|
| Size and price | ||
| Market cap | $2.9M | $78.2M |
| Share price | $0.225 | $2.39 |
| Change, 1 year | – | −64.9% |
| Change, 5 years | – | −95.7% |
| Beta (5Y) | – | 1.12 |
| Employees | 14 | 58 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× (better) | 46.8× |
| P/B | 1.8× | – |
| FCF yield | – | −39.6% |
| Fair value | $0.553 | – |
| Margin of safety | 59.3% | – |
| Growth | ||
| Revenue growth (TTM) | 16.7% (better) | −60.8% |
| Revenue growth, 5Y average | – | 27.2% |
| Profitability | ||
| Gross margin | 29.6% | 48.3% (better) |
| Operating margin | −163% (better) | −3012% |
| Net margin | −183% (better) | −2956% |
| FCF margin | – | −1856% |
| Return on equity | −239% | – |
| Financial health | ||
| Interest coverage | −21.3× | – |
| Current ratio | 1.99 | 2.00 (better) |
| Altman Z-score | −8.83 (better) | −24.03 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −33.3% |
| Shareholder yield | 0.00% (better) | −33.3% |
| Ownership | ||
| Held by institutions | 4.2% | 56.4% |
| Held by insiders | 14.8% | 81.6% |
| Insider net buying, 12 months | – | $5.7M |
| Short interest, % of float | 0.52% | 17.0% |
Go deeper
- AIDX stock overview
- AIDX income statement
- AIDX valuation and score
- IMDX stock overview
- IMDX income statement
- IMDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.